Mary F. Brunette, MD
Title(s):
Professor of Psychiatry
Professor of Community and Family Medicine
Professor of The Dartmouth Institute
Additional Titles/Positions/Affiliations:
Medical Director, Bureau of Mental Health Services, NH Dept of Health and Human Services
Co-Director, Northern New England Post-Doctoral Primary Care Research Training Program
Co-DIrector, Community Engaged Research Core, Dartmouth SYNERGY, CTSA
Chairman, NH DHHS Committee for the Protection of Human Subjects
Co-Investigator, Ctr for Technology & Behavioral Health
Department(s):
Psychiatry
Community and Family Medicine
The Dartmouth Institute
Education:
Lewis & Clark College, BA 1985
Oregon Health Sciences University, MD 1991
Programs:
C. Everett Koop Institute at Dartmouth
Norris Cotton Cancer Center
Psychopharmacology Research Group
SYNERGY
Other
Contact Information:
Department of Psychiatry, Dartmouth-Hitchcock
Center for Technology and Behavioral Health
46 Centerra Parkway, level 2
Lebanon NH 0
Phone: 603-646-7019
Email: Mary.f.brunette@dartmouth.edu
Assistant: Brian Goodness
Asst. Email: Brian.d.goodness@dartmouth.edu
Professional Interests:
The goal of my research is to better understand the causes of addiction in vulnerable, complex populations, and to develop effective and disseminable treatment interventions for addiction in these groups by using a translational science approach that includes basic science, patient-oriented treatment and population-based studies.
In addition, I am engaged with public mental health administration in which I advance improvements in care for people with serious mental illness and multiple comorbidities.
Grant Information:
ProHealth NH: New Hampshire Partnerships to Improve Health & Wellness for Young People with SED and SMI
1H79SM080245-01 Substance Abuse and Mental Health Administration
Cannabis, schizophrenia and reward: Self-Medication and agonist
1R01DA034699-01 National Institute on Drug Abuse
Comparative effectiveness of integrated vs. referral-based care for pregnant women with opioid use disorder (Lord and Goodman, Multiple PIs)
MAT-2017C2-7717 PCORI
Stemming the Tide: The Role of Payment and Delivery System Reform in
Combating the Opioid Epidemic (Colla PI)
4R01-DA049757-01A1 National Institute on Drug Abuse
Mentoring Information:
I currently lead several large studies, including a trial using functional magnetic resonance imaging to assess the impact of cannabis on brain reward function in schizophrenia, and the implementation of integrated primary care and community mental health.
I am trained as an “Entering Mentoring” Facilitator, with a goal of increasing quality, equity and inclusion in science mentoring. I mentor research trainees on a variety of projects across the translational range - from a secondary analyses describing substance use in young adults with multiple morbidities, to a literature review of impact of cannabis on psychosis, to usability testing of apps for the treatment of addiction, and a qualitative study of a learning community to support statewide implementation of clinical services.
Selected Publications: |
|
Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014-2016. Integrated vs nonintegrated treatment for perinatal opioid use disorder: retrospective cohort study. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Usability and Acceptability of Two Smartphone Apps for Smoking Cessation Among Young Adults With Serious Mental Illness: Mixed Methods Study. Acceptability and Usability of Mobile Apps for Smoking Cessation Among Young Adults With Psychotic Disorders and Other Serious Mental Illness. In Memory of Alan I. Green. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Workshop on Implementation Science and Digital Therapeutics for Behavioral Health. Perceptions of Mobile Apps for Smoking Cessation Among Young People in Community Mental Health Care: Qualitative Study. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial. |
|